6CM
EBS icon

683 Capital Management’s Emergent Biosolutions EBS Stock Holding History

683 Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-92,691
Closed -$886K – 170
2024
Q4 		$886K Buy
+92,691
New +$851K 0.05% 112

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

683 Capital Management's EBS Position: Q1 2025 in Review

683 Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 92,691 shares — an estimated $886K sold.

683 Capital Management first reported a position in EBS in Q4 2024 and held it in 1 quarter. The position peaked at $886K in Q4 2024. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

  • 683 Capital Management reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
  • 683 Capital Management sold 92,691 Emergent Biosolutions shares in Q1 2025, an estimated $886K.
  • 683 Capital Management first reported a position in Emergent Biosolutions in Q4 2024 and held it in 1 quarter.
  • 683 Capital Management's Emergent Biosolutions position peaked at $886K in Q4 2024.
  • 160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.